• GIPR, gastric Inhibitory polypeptide receptor, belongs to the G-protein coupled receptor family. GIPR is expressed in many tissues, including the pancreas, stomach, brain, liver, etc. This protein plays a crucial role in regulating insulin secretion, glucose, and lipid metabolism. Mutations or changes within this gene have been associated with various health conditions, including obesity and diabetes (DOI: 10.1111/j.2040-1124.2010.00022.x).
• Gene targeting strategy for B-Gipr KO mice. The genome sequences between part of exon 3 to the exon 14 in the mouse Gipr gene were depleted in B-Gipr KO mice.
• mRNA expression analysis: Mouse Gipr mRNA was detectable only in wild-type C57BL/6JNifdc mice but not in B-Gipr KO mice.
• In vivo function of LAGIPRA during OGTT: Blood glucose levels decreased significantly following treatment with LAGIPRA in wild-type C57BL/6JNifdc mice. And in B-GIPR KO mice, no obvious decrease in blood glucose was detected after administration of LAGIPRA

Gene targeting strategy for B-Gipr KO mice. The genome sequences between part of exon 3 to the exon 14 in the mouse Gipr gene were depleted in B-Gipr KO mice.

Strain specific analysis of Gipr mRNA expression in wild-type C57BL/6JNifdc mice and B-Gipr KO mice by RT-PCR. Brain RNA were isolated from wild-type C57BL/6JNifdc mice (+/+, 6-week-old), homozygous B-Gipr KO mice (-/-, 6-week-old), and then cDNA libraries were synthesized by reverse transcription, followed by PCR with mouse Gipr primers. Mouse Gipr mRNA was detectable in wild-type mice but not in B-Gipr KO mice.

In vivo function of LAGIPRA during Oral Glucose Tolerance Test (OGTT). C57BL/6JNifdc mice (male, 9-week-old) and homozygous B-Gipr KO mice (male, 9-week-old) were grouped according to body weight, with 6 mice per group, fasted for 16 hours, and subcutaneously injected with LAGIPRA (provided by a client) at a dose of 1.72 mg/mL, 5 μL/g at    -30 min. Plasma glucose and insulin concentrations were measured at 0 min (before glucose administration), and the OGTT was performed with 20% Glucose. (A) Blood glucose at 0-, 15-, 30-, 60-, 90-, and 120 min. (B) Blood glucose AUC, Analyzed by one-way ANOVA, *P<0.05, **P<0.01, ***P<0.001, **** P<0.0001. (C) Plasma insulin at 0-, 15-, 30-, and 60 min. Analyzed by 2way-ANOVA,*P<0.05, **P<0.01, ***P<0.001. Data represent means ± SEM.

Note: This data is from a collaborative project.